Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatm...

Full description

Bibliographic Details
Main Authors: Danilo Rocco, Alex Friedlaender, Alfredo Addeo, Marina Chiara Garassino, Diego Signorelli, Alessandro Russo, Vincenzo Sforza, Alessio Cortellini, Katia Cannita, Daniele Santini, Pietro Di Marino, Federica Zoratto, Marco Russano, Paolo Marchetti, Francesca Rastelli, Rossana Berardi, Rita Chiari, Alain Gelibter, Giampiero Porzio, Paolo Bironzo, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Diego L Cortinovis, Francesco Passiglia, Mariangela Torniai, Carlo Genova, Alessandro Inno, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Miriam G Ferrara, Lorenza Landi, Luigi Della Gravara, Serena Ricciardi, Alessandro De Toma, Vincenzo Adamo, Alessandro Leonetti, Ettore D'Argento, Erika Rijavec, Annalisa Guida, Marco Siringo, Marianna Macerelli, De Tursi Michele, Antonino Grassadonia, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Giulio Metro, Gian Paolo Spinelli
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/4/e002421.full

Internet

https://jitc.bmj.com/content/9/4/e002421.full

Similar Items